https://www.selleckchem.com/products/ox04528.html
The purpose of this study was to determine the effect of patisiran on the cardiac amyloid load as measured by cardiac magnetic resonance and extracellular volume (ECV) mapping in cases of transthyretin cardiomyopathy (ATTR-CM). Administration of patisiran, a TTR-specific small interfering RNA (siRNA), has been shown to benefit neuropathy in patients with hereditary ATTR amyloidosis, but its effect on ATTR-CM remains uncertain. Patisiran was administered to 16 patients with hereditary ATTR-CM who underwent assessment protocols atthe UK N
Gefällt mir
Kommentar
Teilen
